AbbVie secures four non-institution decisions for Humira® patent

Finnegan client AbbVie Inc. fended off multiple petitions filed by biosimilar developer Coherus Biosciences, seeking inter partes review (IPR) of a patent related to certain formulations of adalimumab, the antibody in AbbVie’s anti-inflammatory drug Humira®. The Patent Trial and Appeal Board (PTAB) issued four decisions, each denying institution and holding that Coherus failed to demonstrate a reasonable likelihood of prevailing at trial as to the unpatentability of any challenged claim.